PCR Technologies Market Forecast 2030: Industry Size, Share, Emerging Innovations, and Strategic Growth Plans

The PCR technologies market valued at US$13.88 billion in 2023, is forecasted to grow at a robust CAGR of 7.0%, reaching US$14.61 billion in 2024 and an impressive US$21.89 billion by 2030.

Many factors that drive market growth are interlinked. For instance, advancements in technology support growth. Simultaneously, application in diagnostic labs increases their use in various healthcare settings. There is also a more significant trend in personalized medicine, driving the demand for this market. Higher applications in life sciences, such as disease detection, genomics, and cell analysis, further expand its application. Increased investment by the public and private sector and higher awareness increases the application of this device.

The escalating prevalence of infectious diseases has prompted organisations such as the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) of the US to facilitate the approval processes of PCR testing devices along with other associated technologies. Notably in the era of COVID-19, such speedy approvals have been beneficial in addressing efficiently the management of public health crises and in the quick deployment of diagnostic solutions. Considering these aspects, Government agencies tend to be influential in an economy and as such, the market for PCR technology is relatively more active encouraging the market’s resilience to emerging health challenges.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=96291811

KEY PLAYERS IN THE PCR TECHNOLOGIES MARKET INCLUDE

Driving Forces: Technological Advancement

Advances in technology have dramatically improved the sensitivity, specificity, and efficiency of PCR techniques. Newer techniques, such as real-time PCR and digital PCR, have undergone a drastic transformation that makes them more sensitive and precise. Indeed, applications of PCR have dramatically increased within the past few years. It has become a tool for genetic research and personalized medicine. Furthermore, PCR has become more accessible by coupling it with microfluidics and further advanced automation, making it more efficient in the laboratory. New reagents improve the quality and consistency of the results of PCR. Further research in such technologies will offer new opportunities in research and diagnostics.

Also, there has been several progressions due to the miniaturization of point-of-care testing (PoCT)-PCR technology, which includes shortening assay times, reducing reagent volumes, and performing rapid thermal cycling. Notably, the impact of these miniaturized systems has been felt during public health emergencies such as the COVID-19 pandemic, as they facilitated the rapid diagnosis and management of outbreaks. rephrase it in business professional language. Repeated cycle techniques like PCR.Ai have been incorporated in a PCR workflow to make laboratory testing simple and less time consuming by automating the processes of interpreting and validating results. All these technologies advancements helps in growing demand for PCR products in the market.

Restraining Factors: High Costs of Equipment

High investments required to maintain such systems have been one of the factors restraining the market’s growth, mainly amongst small laboratories and healthcare facilities in developing countries, which cannot readily compete with such prices. The high capital requirement for highly advanced PCR instruments discourages many low-capital institutions from implementing PCR technology routinely for diagnosis and research. Such direct financial costs can disadvantage critical applications like infectious disease detection and genetic evaluations. Maintenance costs, consumables, personnel training, and technical support also enhance the long-term sustainability of PCR technology. Laboratories can incur heavy costs associated with acquisition of PCR instruments such as standard PCR, qPCR, RT-PCR machines. The price range is wide owing to the kind, features and operational capabilities of the apparatus in question. The cost is escalating due to factors such as automation, the volume of throughput, how much activities can be multiplexed and their sensitivity. During long and extensive testing operations such as those conducted during the outbreak of the COVID-19 diseases, a need for more than one equipment necessitated substantial construction costs, thereby emphasizing the impact of new developments in technology on healthcare facilities and research organizations.

Opportunities: Emerging Application of PCR Technology

PCR is highly applied in liquid biopsies to analyze circulating tumor DNA (ctDNA) in blood samples. It is a non-invasive method with which it is possible to detect cancer early, monitor progression, and assess the efficiency of treatments after identifying specific genetic changes of ctDNA. PCT Technology is also incorporated into point-of-care diagnostic equipment to diagnose infectious diseases rapidly, such as COVID-19, HIV, and influenza. Such advancements as isothermal PCR and microfluidic PCR systems enable susceptible and precise tests even outside the confines of a lab. This way, it delivers speedy results for health professionals to hasten treatment decisions, especially in regions with less advanced medical infrastructure.

Genomic medicine is increasingly incorporating digital polymerase chain reaction (dPCR) technology into its usage especially for minimal residual disease monitoring, rare mutation screening, and gene expression assaying. Its high sensitivity and quantitative power greatly suit these applications. Recent developments in techniques like photonic PCR and extreme PCR, which enhance amplification and detection rates, justify the use of these techniques even in point of care, rapid testing environments.

Challenges: Inhibition and Sensitivity

The significant inhibitory challenges in PCR technologies are inhibition and sensitivity, making these technologies less precise and ineffective in all applications. PCR processes are prone to inhibitors in biological samples like blood, soil, or food. Such an inhibitor can interfere with the DNA polymerase enzyme’s ability to amplify DNA. Some examples of these inhibitors include substances like hemoglobin, bile salts, and chemicals from DNA extraction procedures. When it is present, it can block or even totally prevent the amplification of the DNA, which leads to false negatives or partial results.

Despite being extremely sensitive, there are certain limitations. PCR does not amplify DNA efficiently at low concentrations of the target, like infections in the early stages of a disease or those genetic mutations that occur in less than one percent of a population. External DNA contamination is also shown as false positives. The challenge here is maintaining the sensitivity of the technique whereby the minimal amounts of DNA can be sensed without allowing contamination or non-specific amplification, which remains a significant issue in PCR technologies.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=96291811

In the PCR technologies market, the following players hold maximum value shares. They are: F. Hoffman-La Roche Ltd. is headquartered in Switzerland, Thermo Fisher Scientific, Inc. (US), Bio-Rad Laboratories, Inc. in (US), QIAGEN (Germany), Takara Bio, Inc. (Japan), Agilent Technologies, Inc. (US), and Standard Biotools (U.S.), Lonza (Switzerland), Danaher Corporation (U.S.), Abbott Laboratories (U.S.), Merck KGaA (Germany), Bioneer Corporation (South Korea), PerkinElmer Inc. (U.S.), Hologic Inc. (U.S.), Sansure Biotech Inc. (China), Becton, Dickinson and Company (U.S.), and Analytik Jena AG (Germany).

Reagents and consumables to register most significant market share during study period

In PCR, the reagents are the chemicals necessary to amplify DNA, including the primer, nucleotides, DNA polymerase, buffers, etc. The consumables are single-use items such as PCR tubes, plates, pipette tips, and sealing films, used in every PCR procedure but discarded afterward. Reagents and consumables constitute the largest market share for PCR technologies since they are essential for every PCR, unlike PCR instruments. It includes new reagents, such as primers, nucleotides, enzymes, and consumables in tubes and plates. There is a steady demand for high-throughput laboratories for diagnostics and research in which multiple PCR tests can run. Moreover, the vast range of applications in clinical diagnostics, genetic research, and forensic analysis often need specialized reagents, which drives up the market share in this segment.The advent of disease diagnosis through PCR, more particularly after the onset of COVID-19, has significantly increased the consumption of reagents such as enzymes, primers, probes, among other consumables. However, the development of new formulative reagents has brought in additional usage as they have enhanced the sensitivity and specificity and enabled multiplexing. Given all these factors, the demand growth of the reagent market is likely to persist for as long as there are clinical diagnostics and research undertakings in the broader phenomenon of PCT technology, which incorporates PCR technology.

Diagnostic laboratories to hold largest share in end-user market from 2024 to 2030

Diagnostic laboratories are leaders in the PCR market since they play a critical role in diagnosing and prognostic diseases. PCR is commonly used for diagnosing infectious diseases such as novel COVID-19, HIV, and hepatitis; genetic diseases; and cancer because of the accuracy and quick generation of results. The continued use of PCR technologies in the market for screening and real-time testing boosts the need for molecular diagnostics, driving growth in this market. Aside from that, the appearance of personalized medicine and high awareness of the early detection of diseases has heightened their dependency on PCR in such laboratories. Moreover, the persistent requirement for routine tests, especially during pandemics and epidemics, further enhances their market presence. The demand for PCR technology is on rise since the diagnostic labs have to carry out extensive testing in different disease areas such as infectious diseases, cancer or genetic disorders. Furthermore, the importance of diagnostic laboratories as the main consumers of PCR technology has also been strengthened owing to the increasing attention being given to molecular diagnostics in the context of precision medicine as well as in the search for new pathogens.

Recent Developments of PCR Technologies Market

Agreements: In 2023, Bio-Rad Laboratories, Inc. and QIAGEN entered into an agreement to settle their patent dispute pending in the US District Court of Delaware according to a global settlement and patent cross-licensing agreement relating to digital PCR technology.
Partnership: In 2023, Thermo Fisher Scientific (US) partnered with Pfizer (US) to gain access to NGS-associated testing for cancer.
Acquisition: In 2024, F. Hoffman-La Roche Ltd. (Switzerland) acquired TIB Molbiol (Germany) to include infectious diseases in its PCR products portfolio.
Agreement: In 2022, Bio-Rad Laboratories Inc. (US) entered into an agreement with NuProbe (US) to expand its business to multiplexed digital PCR assays.

For more information, Inquire Now!

Content Source:

https://www.prnewswire.com/news-releases/pcr-technologies-market-to-hit-usd-21-89-billion-by-2030-with-7-7-cagr–marketsandmarkets-302272617.html

https://www.marketsandmarkets.com/PressReleases/pcr-technologies.asp

https://www.marketsandmarkets.com/Market-Reports/pcr-technologies-market-96291811.html

Tags:PCR Technologies Market